TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22421197

Group type: EXPERIMENTAL
Intervention: Exposure to EMF in incubators
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Post-removal from incubators to cribs
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (not exposed to EMF)
Number of subjects: 28
Study: 20819220

Group type: EXPERIMENTAL
Intervention: Carbon ion boost applied to the macroscopic tumor up to a total dose of 18 Gy E in 6 fractions at a single dose of 3 Gy E.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proton boost applied up to a total dose of 10 Gy E in 5 single fractions of 2 Gy E.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbon ion boost
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proton boost
Number of subjects: 0
Study: 18814836

Group type: EXPERIMENTAL
Intervention: Porcine pancreatic lipase (PPL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pancreatic extracts (PE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indirect PPL assay
Number of subjects: 0
Study: 16671415

Group type: EXPERIMENTAL
Intervention: Decompressive craniectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 12732586

Group type: EXPERIMENTAL
Intervention: Aspirin (100 mg/d) before bedtime
Number of subjects: 100

Group type: COMPARATOR
Intervention: Aspirin (100 mg/d) on awakening
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonpharmacological hygienic-dietary recommendations
Number of subjects: 100
Study: 10821360

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 12763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12763
Study: 9032748

Group type: EXPERIMENTAL
Intervention: Low-dose estrogens (0.625 mg of conjugated estrogens)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Tibolone
Number of subjects: 72
Study: 8362899

Group type: EXPERIMENTAL
Intervention: Stamped packets (prepaid postage)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Unstamped packets (no prepaid postage)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Stamped packets (indigent patients)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Unstamped packets (indigent patients)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Stamped packets (private insurance patients)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Unstamped packets (private insurance patients)
Number of subjects: 325
Study: 3719163

Group type: EXPERIMENTAL
Intervention: Low dose ultrasound treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 40
Study: 29447770

Group type: EXPERIMENTAL
Intervention: Short-term dual antiplatelet therapy (DAPT)
Number of subjects: 7242

Group type: EXPERIMENTAL
Intervention: Long-term dual antiplatelet therapy (DAPT)
Number of subjects: 7242
Study: 26817879

Group type: EXPERIMENTAL
Intervention: M72/AS01
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 24521675

Group type: EXPERIMENTAL
Intervention: Humidification using the Fisher & Paykel Healthcare MR880 humidifier
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Humidification in compliant PP patients
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Humidification (HNRQ PP analysis)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control arm (no humidification)
Number of subjects: 210
Study: 22794532

Group type: EXPERIMENTAL
Intervention: Social and cognitive stressor before the risk-taking battery
Number of subjects: 89

Group type: COMPARATOR
Intervention: No stress condition (control)
Number of subjects: 89
Study: 20458203

Group type: EXPERIMENTAL
Intervention: Psychological Inoculation (PI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ventilation
Number of subjects: 0
Study: 17651416

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187
Study: 16329022

Group type: EXPERIMENTAL
Intervention: Transnasal EGD (XP-N)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Transoral EGD with small-caliber endoscope (XP-O)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Transoral EGD with conventional endoscope (XQ)
Number of subjects: 450
Study: 11917284

Group type: EXPERIMENTAL
Intervention: Amifostine (500 mg intravenously, twice weekly before chemoradiation)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chemoradiation without amifostine
Number of subjects: 60
Study: 7942476

Group type: EXPERIMENTAL
Intervention: Dobutamine echocardiography
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resting thallium‐201 scintigraphy
Number of subjects: 0
Study: 3236328

Group type: EXPERIMENTAL
Intervention: Diltiazem 180 mg once daily
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Diltiazem 90 mg twice daily
Number of subjects: 8

Group type: COMPARATOR
Intervention: Wash-out period
Number of subjects: 8
Study: 31880586

Group type: EXPERIMENTAL
Intervention: Arteriovenous fistula (AVF) usage for more than 8 months
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Central venous catheter (CVC) usage for less than 4.2 months
Number of subjects: 705

Group type: COMPARATOR
Intervention: Less than 2.8 months of AVF usage
Number of subjects: 705

Group type: COMPARATOR
Intervention: More than 9.2 months of CVC usage
Number of subjects: 705
Study: 29231317

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 61

Group type: COMPARATOR
Intervention: Estazolam
Number of subjects: 61
Study: 26574300

Group type: EXPERIMENTAL
Intervention: Potentiated ZPT shampoo
Number of subjects: 0
Study: 22942402

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural education intervention
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (information leaflet)
Number of subjects: 110
Study: 21485668

Group type: EXPERIMENTAL
Intervention: PercuTwist
Number of subjects: 87

Group type: COMPARATOR
Intervention: Griggs' forceps dilational tracheostomy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 87
Study: 19909590

Group type: EXPERIMENTAL
Intervention: Cimicifuga racemosa (phytoestrogen)
Number of subjects: 134

Group type: COMPARATOR
Intervention: ethinyl oestradiol
Number of subjects: 134
Study: 16169093

Group type: EXPERIMENTAL
Intervention: Intranasal mometasone furoate monohydrate 100 mcg/day
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 122
Study: 15202297

Group type: EXPERIMENTAL
Intervention: ACE inhibitors, beta-blockers, and aldosterone antagonists (combined therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors, beta-blockers, and aldosterone antagonists (individual drugs)
Number of subjects: 0
Study: 11388000

Group type: EXPERIMENTAL
Intervention: Alpha 2-macroglobulin (alpha 2M) and transferrin (Tf) concentrations
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Microheterogeneity of alpha 2M and Tf
Number of subjects: 13
Study: 9241006

Group type: EXPERIMENTAL
Intervention: Gepirone (10 to 45 mg daily)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Diazepam (19.5 +/- 12.5 mg/day)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Gepirone
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 198
Study: 8309606

Group type: EXPERIMENTAL
Intervention: e.v. immunoglobulins (300 mg/kg per day, for three days)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: e.v. immunoglobulins associated with routine antibiotic prophylaxis
Number of subjects: 89

Group type: COMPARATOR
Intervention: Routine antibiotic prophylaxis
Number of subjects: 89
Study: 2894903

Group type: EXPERIMENTAL
Intervention: Group A: tubocurarine (DTC) 3 mg + succinylcholine 1.5 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group B: atracurium 0.05 mg.kg‐1 + 0.35 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group C: vecuronium, 0.01 mg.kg‐1 + 0.07 mg.kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Group D: no relaxant
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group E: DTC 0.05 mg.kg‐1 + vecuronium 0.07 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group F: vecuronium 0.01 mg.kg‐1 + vecuronium 0.12 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group G: DTC 3 mg + succinylcholine 1.5 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group H: vecuronium 0.01 mg.kg‐1 + 0.09 mg.kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group I: vecuronium 0.1 mg.kg‐1 as a single bolus
Number of subjects: 0
Study: 30838799

Group type: EXPERIMENTAL
Intervention: Preoperative antibiotics (AB group)
Number of subjects: 447

Group type: COMPARATOR
Intervention: No antibiotics (noAB group)
Number of subjects: 447
Study: 29038203

Group type: EXPERIMENTAL
Intervention: CPAP plus Weight Loss
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Weight Loss
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 139
Study: 26133933

Group type: EXPERIMENTAL
Intervention: NIRS (Near-Infrared Spectroscopy)
Number of subjects: 79

Group type: COMPARATOR
Intervention: No NIRS (Control)
Number of subjects: 79
Study: 21787375

Group type: EXPERIMENTAL
Intervention: Integrated-low group
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Traditional Hispanic group
Number of subjects: 114
Study: 22626945

Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5 mg, increased to a maximum of 2 mg daily)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Ginkgo biloba (40 mg, increased to a maximum of 160 mg daily)
Number of subjects: 38
Study: 19386096

Group type: EXPERIMENTAL
Intervention: XELIRI (irinotecan 250 mg/m² on day one, capecitabine 1000 mg/m² twice daily from day 2-15, every 21 days)
Number of subjects: 87

Group type: COMPARATOR
Intervention: FOLFIRI (irinotecan 180 mg/m², 5-FU 400 mg/m², LV 200 mg/m², 5-FU 2400 mg/m² (46-h infusion) on day one, every 14 days)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: XELIRI
Number of subjects: 87

Group type: COMPARATOR
Intervention: FOLFIRI
Number of subjects: 87
Study: 17879083

Group type: EXPERIMENTAL
Intervention: Sclerosing polidocanol injections (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Open surgical revision (Group B)
Number of subjects: 20
Study: 14716731

Group type: EXPERIMENTAL
Intervention: Disease-modifying therapies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surrogate markers (brain imaging)
Number of subjects: 0
Study: 11552906

Group type: EXPERIMENTAL
Intervention: Loxiglumide infusion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 19
Study: 9559415

Group type: EXPERIMENTAL
Intervention: Saline loading (250 ml of normal saline) with ACE inhibitor (delapril) after 5 days
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Saline loading (250 ml of normal saline) without ACE inhibitor
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (10 control subjects)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ACE inhibitor (delapril)
Number of subjects: 10
Study: 7513981

Group type: EXPERIMENTAL
Intervention: Urinary myelin basic protein-like material (MBPLM) in MS patients
Number of subjects: 166

Group type: COMPARATOR
Intervention: Urinary MBPLM in MS patients
Number of subjects: 166

Group type: COMPARATOR
Intervention: Treatment with glucocorticoids and immunosuppressants
Number of subjects: 166

Group type: COMPARATOR
Intervention: Urinary MBPLM in patients with cranial magnetic resonance imaging
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Urinary MBPLM
Number of subjects: 166
Study: 3299182

Group type: EXPERIMENTAL
Intervention: Vitamin B6 supplementation (150 mg daily)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 30700145

Group type: EXPERIMENTAL
Intervention: HIV/AIDS media exposure
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: HIV/AIDS knowledge
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: HIV/AIDS attitude
Number of subjects: 500
Study: 28334958

Group type: EXPERIMENTAL
Intervention: Self-help smoking relapse prevention intervention using the 'Forever Free' self-help booklets.
Number of subjects: 43
Study: 28599953

Group type: EXPERIMENTAL
Intervention: Nap group
Number of subjects: 28

Group type: COMPARATOR
Intervention: No Nap group
Number of subjects: 28
Study: 25817527

Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active and passive controls
Number of subjects: 0
Study: 24283110

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg (n=98)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg (n=94)
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Contrast agent administered
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: Left ventricular ejection fraction
Number of subjects: 192
Study: 21275437

Group type: EXPERIMENTAL
Intervention: Clopidogrel therapy (600 mg loading dose and 75 mg/day maintenance dose) plus aspirin (300 mg/day)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (patients aged <75 years)
Number of subjects: 149
Study: 17952589

Group type: COMPARATOR
Intervention: Raloxifene (60 mg PO daily)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Exemestane (25 mg PO daily)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Combination therapy (Raloxifene 60 mg PO daily + Exemestane 25 mg PO daily)
Number of subjects: 11
Study: 16317581

Group type: EXPERIMENTAL
Intervention: Low-fat diet
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: High vegetable-fruit diet
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Increasing plasma levels of lutein
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Increasing plasma levels of alpha-carotene
Number of subjects: 71
Study: 14650558

Group type: EXPERIMENTAL
Intervention: Universal barrier precautions (gloves, gowns, masks, hats, facial shields, glasses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surface disinfectants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pre-op 0.12% chlorhexidine mouth rinses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High volume evacuation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perioral skin scrubs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rubber dam isolation, hand excavation and bond technique, high-speed air turbine and electric 'high' speed handpiece
Number of subjects: 0
Study: 11155450

Group type: EXPERIMENTAL
Intervention: Phospholax solution (one dose in the evening two days before the examination and four doses the day before, two in the afternoon and two in the evening, followed by abundant hydration)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Traditional method (residue‐free diet for three days, sennoside-based laxative the morning before, magnesium sulphate in the afternoon)
Number of subjects: 80
Study: 8973005

Group type: EXPERIMENTAL
Intervention: Nutrient supplemented preterm formula
Number of subjects: 926

Group type: COMPARATOR
Intervention: Standard formula milk
Number of subjects: 926

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 926
Study: 1289019

Group type: EXPERIMENTAL
Intervention: Bedtime insulin (BTI)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Morning insulin (MI)
Number of subjects: 9
Study: 3881323

Group type: EXPERIMENTAL
Intervention: d-penicillamine 1200 mg daily
Number of subjects: 189

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: d-penicillamine
Number of subjects: 189
Study: 30759235

Group type: EXPERIMENTAL
Intervention: Sour cream
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 47
Study: 29143707

Group type: EXPERIMENTAL
Intervention: UltraRice®Original
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: UltraRice®New
Number of subjects: 1796

Group type: EXPERIMENTAL
Intervention: NutriRice®
Number of subjects: 1796

Group type: COMPARATOR
Intervention: Normal rice
Number of subjects: 1796
Study: 26479169

Group type: EXPERIMENTAL
Intervention: Early feeding (within 6 hours post-surgery)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Late feeding (after 12 hours post-surgery)
Number of subjects: 177
Study: 24891548

Group type: EXPERIMENTAL
Intervention: Intervention with systems of support for completion of colorectal cancer screening
Number of subjects: 4675

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4675
Study: 23171304

Group type: EXPERIMENTAL
Intervention: Recovery focused CBT (RfCBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 20047560

Group type: EXPERIMENTAL
Intervention: Fenofibrate 145 mg/day
Number of subjects: 15

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 15
Study: 18257348

Group type: EXPERIMENTAL
Intervention: Common acupuncture group (traditional acupoint selection method)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Balance yin-yang acupuncture group (combined acupoints on yin and yang channels)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (routine medicine and rehabilitation training only)
Number of subjects: 96
Study: 15130637

Group type: EXPERIMENTAL
Intervention: New phacoemulsification technology
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previously published results for the same machines before the new technology
Number of subjects: 0
Study: 11722858

Group type: EXPERIMENTAL
Intervention: Intervention group with extra guidelines for the teacher (38 pupils)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intervention group without extra guidelines (48 pupils)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Candid camera evaluation for intervention group with guidelines (38 pupils)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Candid camera evaluation for intervention group without guidelines (48 pupils)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (34 pupils)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Knowledge test scores for both intervention groups
Number of subjects: 120
Study: 10051930

Group type: EXPERIMENTAL
Intervention: Propofol (group P, n = 26)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S, n = 26)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Propofol (group P)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S, n = 24)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Propofol (group P, n = 2-5)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sevoflurane (group S, n = 13)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Propofol (group P, n = 12)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Ambulatory anaesthesia failure
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Reoperation needed
Number of subjects: 52
Study: 7973477

Group type: EXPERIMENTAL
Intervention: Ximoprofen 5 mg daily
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Ximoprofen 10 mg daily
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Ximoprofen 20 mg daily
Number of subjects: 285

Group type: EXPERIMENTAL
Intervention: Ximoprofen 30 mg daily
Number of subjects: 285

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study: 2586204

Group type: EXPERIMENTAL
Intervention: Xipamide 20 mg once a day for 16 weeks
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 1100213

Group type: EXPERIMENTAL
Intervention: Alpha methyldopahydrazine in combination with L-dopa
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo with L-dopa
Number of subjects: 25
Study: 31896491

Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day for 3 months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30926571

Group type: EXPERIMENTAL
Intervention: Philani home‐visiting condition (HVC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care condition (SC)
Number of subjects: 0
Study: 29236049

Group type: EXPERIMENTAL
Intervention: Vitamin D₃ 200,000 IU followed by monthly 100,000 IU doses (n = 226)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Placebo monthly (n = 216)
Number of subjects: 442
Study: 26003640

Group type: EXPERIMENTAL
Intervention: Imipenem administered every 6 hours
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Imipenem administered every 8 hours
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CVVH mode with actual dose of replacement fluid (31.63±1.48) mL×kg⁻¹×h⁻¹
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: AN69 filter
Number of subjects: 25
Study: 23078984

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MBI-ld)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Lifestyle education program (active control)
Number of subjects: 186
Study: 21594660

Group type: EXPERIMENTAL
Intervention: Inpatient pain therapy for 3 weeks
Number of subjects: 200
Study: 18758373

Group type: EXPERIMENTAL
Intervention: Immediate-release omeprazole 40 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Delayed-release lansoprazole 30 mg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Delayed-release pantoprazole 40 mg
Number of subjects: 55
Study: 16224141

Group type: EXPERIMENTAL
Intervention: Men aged 50-64 years
Number of subjects: 5670

Group type: EXPERIMENTAL
Intervention: Women aged 20-49 years
Number of subjects: 5670

Group type: EXPERIMENTAL
Intervention: Older population (both genders)
Number of subjects: 5670

Group type: EXPERIMENTAL
Intervention: Younger population (both genders)
Number of subjects: 5670
Study: 11872684

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 19
Study: 10453833

Group type: COMPARATOR
Intervention: Normal pregnancy (third trimester)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Pre-eclampsia
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: All groups (pre-eclamptic, normal pregnant, nonpregnant)
Number of subjects: 48
Study: 7788682

Group type: EXPERIMENTAL
Intervention: Enalapril maleate (ACE inhibitor) for six weeks
Number of subjects: 30
Study: 2347046

Group type: EXPERIMENTAL
Intervention: Sequential alternating drug regimen consisting of Adriamycin-cisplatin + vincristine-cyclophosphamide + high-dose methotrexate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Combination of Adriamycin-cyclophosphamide
Number of subjects: 200

Group type: COMPARATOR
Intervention: Combination of Adriamycin-cisplatin
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: High-dosed ifosfamide (used in pilot studies)
Number of subjects: 200